VATE INNOVATE Corp.

NYSE innovatecorp.com


$ 5.26 $ 0.54 (11.51 %)    

Tuesday, 21-Oct-2025 15:57:52 EDT
QQQ $ 610.44 $ -0.16 (-0.03 %)
DIA $ 469.29 $ 2.20 (0.47 %)
SPY $ 671.22 $ -0.01 (0 %)
TLT $ 91.98 $ 0.45 (0.49 %)
GLD $ 379.55 $ -25.91 (-6.43 %)
$ 5.23
$ 4.91
$ 5.04 x 200
$ 5.30 x 100
$ 4.72 - $ 5.50
$ 3.71 - $ 13.79
184,961
na
69.75M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-10-2018 05-10-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 innovate-announces-medibeacons-transdermal-gfr-system-receives-nmpa-approval-in-china-plans-year-end-launch

•MediBeacon®Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patient...

 innovate-q2-eps-167-down-from-100-yoy-sales-24200m-down-from-31310m-yoy

Innovate (NYSE:VATE) reported quarterly losses of $(1.67) per share. This is a 267 percent decrease over earnings of $1.00 per ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION